Sheaff Brock Investment Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Sheaff Brock Investment Advisors, LLC
- $1.14 Billion
- Q4 2024
A detailed history of Sheaff Brock Investment Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheaff Brock Investment Advisors, LLC holds 7,747 shares of HALO stock, worth $438,790. This represents 0.03% of its overall portfolio holdings.
Number of Shares
7,747
Previous 7,118
8.84%
Holding current value
$438,790
Previous $407,000
9.09%
% of portfolio
0.03%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
538Shares Held
124MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$998 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$730 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$376 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$230 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$193 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.89B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...